Robert Goeltz
Director of Finance/CFO chez ARCUS BIOSCIENCES, INC.
Fortune : 1 M $ au 31/03/2024
Profil
Robert C.
Goeltz is currently the Chief Financial Officer at Arcus Biosciences, Inc. He previously held the position of Finance Director at Tularik, Inc. from 2002 to 2004.
From 2013 to 2015, he served as the Chief Financial Officer at Onyx Pharmaceuticals, Inc. He then worked as the Chief Financial Officer & Senior Vice President at CytomX Therapeutics, Inc. from 2015 to 2017.
From 2017 to 2020, he was the Chief Financial Officer at Unity Biotechnology, Inc. Mr. Goeltz completed his undergraduate degree at Goizueta Business School-Emory and holds an MBA from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0,08% | 23/01/2024 | 73 831 ( 0,08% ) | 1 M $ | 31/03/2024 |
Postes actifs de Robert Goeltz
| Sociétés | Poste | Début |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Director of Finance/CFO | 01/08/2020 |
Anciens postes connus de Robert Goeltz
| Sociétés | Poste | Fin |
|---|---|---|
| UNITY BIOTECHNOLOGY, INC. | Director of Finance/CFO | 01/08/2020 |
| CYTOMX THERAPEUTICS, INC. | Director of Finance/CFO | 15/05/2017 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Director of Finance/CFO | 01/05/2015 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01/08/2004 |
Formation de Robert Goeltz
| Goizueta Business School-Emory | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| UNITY BIOTECHNOLOGY, INC. | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
